Dr. Charles James Ryan

Dr. Charles James Ryan, MD, is a genitourinary medical oncologist specializing in advanced and metastatic prostate cancer. He sees patients at the Sidney Kimmel Center for Prostate and Urologic Cancers in New York City and at Memorial Sloan Kettering Monmouth in New Jersey. With a career built around both clinical excellence and meaningful patient relationships, Dr. Ryan takes pride in educating patients and their families about their diagnosis and the full range of treatment options available, including hormonal therapies, chemotherapy, targeted therapy, and radiogland therapy, a treatment that delivers radiation directly to targeted cancer cells. His commitment to establishing long-term relationships with his patients reflects a patient-centered philosophy that has defined his work as a lifelong clinician.

Dr. Ryan has led numerous clinical trials and research teams focused on the biology, treatment, and supportive care of prostate cancer. He has received research funding from the National Institutes of Health, the Department of Defense Prostate Cancer Research Program, and the Prostate Cancer Foundation. He has published more than 200 articles and book chapters in leading medical journals and is the author of "The Virility Paradox: The Vast Influence of Testosterone on Our Bodies, Minds, and the World We Live In," a work that brings his deep expertise in prostate cancer biology to a broad audience. His contributions to the scientific literature have helped shape current understanding of prostate cancer treatment and hormonal mechanisms.

On a national and organizational level, Dr. Ryan has served as Chair of the National Cancer Institute's GU Steering Committee's Prostate Cancer Task Force and as Chief Executive Officer of the Prostate Cancer Foundation. He currently serves as Medical Director of the Prostate Cancer Clinical Trials Consortium and is a member of the Advanced Prostate Cancer Consensus Conference. These roles reflect his standing as a leading voice in prostate cancer research, policy, and clinical trial development, and his ongoing dedication to advancing care for patients with advanced disease.